SUNRISE, Fla., July 2 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced it has been added to the Russell Microcap Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.
According to the Russell Investment Group, the Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The Company will hold its membership until Russell reconstitutes its indexes in June 2009.
"We are pleased with our inclusion in this index, which reflects our continued momentum," said William Kline, Chief Financial Officer, Bioheart, Inc. "We are confident that our inclusion in this index will generate greater interest in our stock among institutional investors."
The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It includes 1,000 of the smallest securities in the small-cap Russell 2000(R) Index based on a combination of their market cap and current index membership as well as the next 1,000 securities below the index.
ABOUT BIOHEART, INC.
Bioheart, Inc. (NASDAQ: BHRT) is a biotechnology company focused on the
discovery, development and, subject to regulatory approval,
commercialization of autologous cell therapies for the treatment of chronic
and acute heart damage. Its lead product candidate, MyoCell(R), is an
innovative clinical cell therapy designed to populate regions of scar
tissue within a patient's heart with
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved